Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado$758,943 Vol.
30 de junho
2%
31 de dezembro
24%
$758,943 Vol.
30 de junho
2%
31 de dezembro
24%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions